Cargando…

Use of dapagliflozin in patients with advanced diabetic kidney disease

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are effective for overweight diabetic patients through the induction of glucosuria. However, SGLT2 inhibitors are not recommended for patients with advanced chronic kidney disease (CKD) because they may aggravate renal function and thus become less e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Hyun Sun, Jung, Youn Joo, Lee, Dong-Young, Moon, Kyoung Hyoub, Kim, Beom, Kim, Hae Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Nephrology 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6147181/ https://www.ncbi.nlm.nih.gov/pubmed/30254854 http://dx.doi.org/10.23876/j.krcp.2018.37.3.292

Ejemplares similares

A Case of Peritoneal Dialysis-related Peritonitis Caused by Aeromonas Hydrophila in the Patient Receiving Automated Peritoneal Dialysis
por: Kim, Hyun Jin, et al.
Publicado: (2018)

A Case Report of Syndrome of Inappropriate Antidiuretic Hormone Induced by Pregabalin
por: Jung, Youn Joo, et al.
Publicado: (2016)

Fournier Gangrene in a Patient With Type 2 Diabetes Mellitus Treated With Dapagliflozin: A Case Report
por: Moon, Jae Young, et al.
Publicado: (2021)

Usefulness of Dapagliflozin for Nephrotic Syndrome Secondary to Diabetic Kidney Disease
por: Murashima, Ryoko, et al.
Publicado: (2022)

Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling
por: Lee, Seul-Gee, et al.
Publicado: (2022)

Clinical Significance of Subjective Foamy Urine
por: Kang, Kyu Keun, et al.
Publicado: (2012)

Diagnostic accuracy of urine dipstick for proteinuria in older outpatients
por: Lim, Dongmin, et al.
Publicado: (2014)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
por: Seong, Jong-Mi, et al.
Publicado: (2021)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes
por: Choi, Jin Bong, et al.
Publicado: (2020)

Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
por: Shin, Seok Joon, et al.
Publicado: (2016)

Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care
por: Huh, Youn, et al.
Publicado: (2022)

Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea
por: Park, Sang Hyun, et al.
Publicado: (2019)

Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension
por: Moon, Jun Sung, et al.
Publicado: (2023)

Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
por: Han, Eugene, et al.
Publicado: (2018)

Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study
por: Seong, Jong-Mi, et al.
Publicado: (2020)

Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
por: Lee, Byung Wan, et al.
Publicado: (2023)

Dapagliflozin in patients with COVID-19: mind the kidneys
por: Reis, Thiago, et al.
Publicado: (2022)

High dose haemodialysis and haemodiafiltration parameters and the relationship with advanced vascular calcification
por: Park, Sung Keun, et al.
Publicado: (2020)

Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin
por: Pujara, Shreya, et al.
Publicado: (2017)

Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy
por: Papadokostaki, Eleni, et al.
Publicado: (2019)

Dapagliflozin Ameliorates Lipopolysaccharide Related Acute Kidney Injury in Mice with Streptozotocin-induced Diabetes Mellitus
por: Chi, Po-Jui, et al.
Publicado: (2022)

Risk Factors for the Development and Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Advanced Diabetic Retinopathy
por: Yun, Kyung-Jin, et al.
Publicado: (2016)

Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease
por: Hong, Ju-Young, et al.
Publicado: (2020)

Mechanism of metastasis to the spermatic cord and testis from advanced gastric cancer: a case report
por: Park, Soyoung, et al.
Publicado: (2020)

Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study
por: Lim, Jaehyun, et al.
Publicado: (2023)

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
por: Koshino, Akihiko, et al.
Publicado: (2023)

Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease
por: Kinguchi, Sho, et al.
Publicado: (2021)

Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial
por: Marx, Nikolaus, et al.
Publicado: (2021)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

Blood Pressure Control in Patients with Diabetic Kidney Disease
por: Kim, Yaeni, et al.
Publicado: (2022)

Increased Malignant Microcalcifications after Neoadjuvant Chemotherapy in Advanced Breast Cancer
por: Shin, Gi Won, et al.
Publicado: (2016)

Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease
por: Choi, Dug-Hyun, et al.
Publicado: (2018)

Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis
por: Badwal, Karun, et al.
Publicado: (2018)

Normoglycemic diabetic ketoacidosis in a type 2 diabetes patient on dapagliflozin: A case report
por: Matli, Venkata Vinod Kumar, et al.
Publicado: (2021)

Prolonged Motor Weakness With Syringomyelia in Japanese Encephalitis: A Case Study
por: Kim, Young Moon, et al.
Publicado: (2015)

Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease
por: van der Aart-van der Beek, Annemarie B., et al.
Publicado: (2021)

Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Hypothermia-induced acute kidney injury in an elderly patient
por: Yoon, Hyun Ju, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pa77k6avnr2jq363jo0hi083ja